Skip to main content

Drug Interactions between Norisodrine with Calcium Iodine and sodium polystyrene sulfonate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sodium polystyrene sulfonate anhydrous calcium iodide

Applies to: sodium polystyrene sulfonate and Norisodrine with Calcium Iodine (anhydrous calcium iodide / isoproterenol)

Sodium polystyrene sulfonate can bind to calcium, iron, magnesium, and other minerals in the gastrointestinal tract. This may inactivate both sodium polystyrene sulfonate and the mineral it binds to and reduce the effectiveness of both medications. To avoid or minimize the interaction, the dosing times of sodium polystyrene sulfonate and anhydrous calcium iodide should be separated by several hours. Talk to your doctor if you have any questions or concerns, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

sodium polystyrene sulfonate food

Applies to: sodium polystyrene sulfonate

Foods high in potassium such as orange juice and other fruit juices may reduce the effectiveness of sodium polystyrene sulfonate in treating your condition. Do not mix sodium polystyrene sulfonate in fruit juice or drink fruit juice with it. Also, sodium polystyrene sulfonate may interfere with the absorption of other medications that you take by mouth, including both prescription medications such as antibiotics, blood pressure/heart medications and blood thinners, and over-the-counter products such as antacids and laxatives. This can lead to lower blood levels and reduced effects if you take them too closely together with sodium polystyrene sulfonate. It is recommended that you separate the dosing of sodium polystyrene sulfonate from other oral medications by at least 3 hours whenever possible. This interval should be increased to 6 hours if you have gastroparesis or other conditions that cause delayed emptying of food from the stomach into the intestine. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

sodium polystyrene sulfonate food

Applies to: sodium polystyrene sulfonate

Sodium polystyrene sulfonate can bind to calcium, iron, magnesium, and other minerals in the gastrointestinal tract. This may inactivate both sodium polystyrene sulfonate and the mineral it binds to and reduce the effectiveness of both medications. To avoid or minimize the interaction, the dosing times of sodium polystyrene sulfonate and multivitamin with minerals should be separated by several hours. Talk to your doctor if you have any questions or concerns, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

isoproterenol food

Applies to: Norisodrine with Calcium Iodine (anhydrous calcium iodide / isoproterenol)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.